Abstract Original Article
Study design and settings
In this retrospective study, all patients of vipoma were investigated. Clinical features, laboratory data at initial presentation, management and outcomes were collected.
Definition
All patients of pNETs since neonate to old-age were investigated. Prevalence of primary and metastatic sites in these patients assessed. Moreover, all symptoms and signs of patients at initial presentation were extracted from articles. Serum electrolytes, creatinine, glucose, hormones, arterial blood gas was investigated in this study. Furthermore, diagnostic methods, treatment modalities and outcomes were examined.
Statistical analysis
Categorical variables are recorded as frequency (N) and percentage (%). Continuous variables are reported as mean ± standard deviation (SD). Comparisons between variables were assessed by F test and two-tailed t test analysis. Significance was assessed with P value of <0.05.
Results

Patient's characteristics
This study selected 30 patients and demographic characteristics of VIPoma are summarized in ' Table 1 '. Mean (± SD) age of patients at time of diagnosis was 50 ± 17.85 years (ranging from 2 to 80 years). Of these, 15 patients (15/30, 50%) were male and 15 patients (15/30, 50%) were female [ Figure 2 ]. 
Anatomic involvement of tumor
Prevalence of primary and metastatic sites of tumors include pancreas (29/30, 96 .6%), liver (14/30, 46 .6%), parathyroid and lymph nodes (3/30, 10%), adrenal gland, pituitary and duodenum (2/30, 6 .6%), stomach, kidney, ovary and sigmoid colon (1/30, 3.3%).
Patient's complaints
Patient's history and physical examination are of paramount importance, especially in the setting of functional pNETs. It classically presents with severe secretory diarrhea with hypokalemia, dehydration and hypochlorhydria. In this and 41 articles were excluded due to non-originality and non-pancreatic NETs. The author reviewed bibliographies of all selected articles (case reports) to identify the additional relevant studies. In presence of non-English papers, they were translated and there were 3 non-English articles (2 case reports and one review article) in this study that were excluded due to unavailable electronic access. 29 published articles included 30 case reports and patients for qualitative and quantitative synthesis [ Figure 1 ]. In this retrospective study, all experimental participants (patients) of pNETs were investigated since neonate to old-age. Prevalence of primary and metastatic sites in these patients assessed. Moreover, all symptoms and signs of patients at initial presentation were extracted from articles. Serum electrolytes, creatinine, glucose, hormones, arterial blood gas was were investigated in this study. Furthermore, diagnostic methods, treatment modalities and outcomes were examined.
Ethical states
This article does not contain examinations performed on human participants directly. Then, ethical approval was not necessary by author of this paper, but case reports' authors mentioned obtaining written consent from their patients in the mentioned case reports. Figure 4 ].
Diagnostic methods
There are different methods for diagnosis of vipoma such as ultrasonography, computed tomography (CT) scan, contrast-enhanced computed tomography (CECT) scan, magnetic resonance imaging (MRI), radiolabeled positron emission tomography-computed tomography (Radiolabeled PET-CT scan), gastrointestinal (GI) endoscopy, ultrasonography-guided needle biopsy, CT-guided needle biopsy, 99technetium-methoxyisobutylisonitrile parathyroid (99TC-MIBI) scintigraphy and somatostatin receptor scintigraphy (SRS) with radiocompound. In this study, diagnostic methods were used for vipoma in 28 patients (28/ Roux-en-Y, whipple procedure, caudal pancreasectomy plus splenectomy, caudal pancreasectomy plus splenectomy plus total hepatectomy, pancreatectomy plus splenectomy plus radiofrequency ablation (RFA) of liver metastasis plus hepatic artery embolization (HAE) plus salpingoophorectomy, pancreaticoduodenectomy plus wedge resection of liver metastasis, body-caudal pancreasectomy plus splenectomy plus left hepatic trisegmentectomy, surgical resection of pancreatic vipoma with gastrointestinal stromal tumor (GIST), head and body resection of pancreas in laparotomy plus left nephrectomy and resection of metastatic nodules of liver and pylorus-preserving pancreaticoduodenectomy plus regional lymphadenectomy plus hepatic resection plus wirsung-jejunustomy in one patient (1/30, 6.6%).
Outcome
Outcome of patients include time lapsed after onset of symptoms (initial time of asymptomatic period) or symptomatic improvement especially diarrhea, recurrence of laboratory findings [hypokalemia, elevated VIP and chromogranin A (CgA)], recurrence of radiological imagings (US, CT scan, MRI), nuclear scintigraphy (octreoscan, VIP scintigraphy) and death. There were symptomatic improvement of diarrhea after surgery or starting drug in 29 patients (29/30, 96.6%) and missing data in one patient (1/30, 3.3%). Lapsed time after onset of symptoms (asymptomatic time) has been characterized in 24 patients (24/30, 80%). There was unrecognized time of disappeared symptoms in 6 patients (6/30, 20%). Lapsed time after onset of symptoms (disappeared time of symptoms after initial presentation) have been estimated with mean ± SD of 2.41 ± 5.46 months. In reported lapsed time after onset of symptom (initial time of asymptomatic period), two groups of age between male and female were compared that mean ± SD of ages in 14 male patients (n = 14/24, 58.3%) has been reported 54.14 ± 14.33 years. Mean ± SD of ages in 10 female patients (n = 10/24, 41.6%) has been reported 47.1 ± 19.57 years. Mean difference between 2 variables (two age groups in males and females) was assessed with P value of 0.37. There was recurrence of diarrhea in 4 patients (4/30, 13.3%) during follow-up that symptoms disappeared in one patient (1/30, 3.3%) after 3 years. Potassium normalization has been occurred after surgery or drug treatment in 5 patients (5/30, 16.6%) and there was persistent hypokalemia in one patient (1/30, 3.3%). There were elevated CgA in 2 patients (2/30, 6.6%) during follow-up. Decreased VIP levels to normal (< 75 pg/ml) have been seen in 15 (15/30, 50%) of case reports that these levels have been reported as quantitative amount after surgery or drug treatment in 10 patients (10/30, 33.3%). There were elevated VIP levels after surgery, drug treatment or during follow-up in two patients (2/30, 50%) with mean ± SD of 24.58 ± 14.57 in males and 25.82 ± 14.93 in females (P = 0.93) [ Table 2 ]. There were elevated CgA in two patients (2/30, 6.6%) during follow-up. Ultrasound in follow-up has been performed in one patient (1/30, 3.3%) that was detected no recurrence. There were recurrence in CT scan in 4 patients (4/30, 13.3%) and prevalence of recurrence in liver was reported in 3 patients (3/30, 10%) during follow-up. There were lymph node and ovary recurrence in one patient with equal rate (1/30, 3.3%). MRI has been performed in 5 patients (5/30, 16.6%) that liver metastasis was detected in one patient (1/30, 3.3%). Nuclear scintigraphy has been performed in 3 patients (3/30, 10%): one VIP scintigraphy and 2 SRS scintigraphy. There were no tumor recurrence on VIP scintigraphy and OctreoScan during 14 and 6 weeks follow-up, but there was recurrence in one patient (1/30, 3 .3%) at 6 and 15 months surveillance. There were regular follow-up in 14 patients (14/30, 46.6%) with mean ± SD duration of 12.06 ± 10.38 months. 3 patients (3/30, 10%) died due to complications such as pancreatic abscess, pulmonary sepsis and sepsis/denutrition. 8 patients (8/30, 26.6%) were alive and symptom-free during the mentioned follow-up duration [ Figure 8 ].
dIscussIon
Pathogenesis
The pathogenesis of pNETs is largely unknown but is growing as a research topic. Approximately 10% of all pNETs are component of familial endocrine tumor syndromes such as MEN-1, von hippel-lindau disease, neurofibromatosis type 1 and tuberous sclerosis. The etiology of pNETs within the context of these familial syndromes is the inherited germline loss of the respective tumor suppressor gene. Several studies have been performed on the pathogenesis of sporadic pNETs, which comprise 90% of all pNETs. Loss of chromosome 1,3p, 6q, 11p or 22q and gains of chromosome 4 or 9q have been observed in pNETs. It is assumed that the loss of a tumor suppressor gene or the gain of an oncogene is the mechanism by which chromosomal alterations cause pNETs, but stochastic chromosomal number changes are also possible. Cyclin D1 oncogene has identified an important role in pathogenesis of human pancreatic endocrine tumors (PETs). [31] In this study, 6.6% of patients inherited vipoma as one of multiple endocrine neoplasia (MEN1) -associated tumors.
Clinical manifestations
VIPomas represent less than of ten percent of functional pNETs and secret vasoactive intestinal polypeptide leading to verner-morrison syndrome, also known as WDHA syndrome or pancreatic cholera, characterized by watery diarrhea, hypokalemia, hypochlorhydria, hyperglycemia, hypercalcemia and dehydration. [32] In this study, all patients presented with watery diarrhea (30/30, 100%), dehydration (10/30, 33.3%), weight loss (9/30, 30%), generalized weakness (6/30, 20%) and other symptoms and signs that above mentioned completely.
Diagnosis
American society concerns diagnostic pathway, imaging techniques [i.e., ultrasound or contrast-enhanced computed tomography or magnetic resonance] are necessary to detect both the primary tumor and metastases. Somatostatin receptor scintigraphy is suggested to detect metastases, including extrahepatic disease, although positron emission tomographic using 68 gallium (68 Ga) appears to be more sensitive, particularly in case of small lesions. Radiolabeled (with Tc-99m, In-111or Ga-68) somatostatin analogs have been used for imaging of NETs. Ultrasound endoscopy is recommended to small pancreatic tumors and to achieve a diagnosis by means of fine needle aspiration. The combination of endoscopic ultrasonography and somatostatin receptor scintigraphy may be able to provide most of the information required preoperatively and seems to be the optimal approach available to date. [33] Laboratory tests, including CgA, pancreatic polypeptide and specific hormones according to clinical presentation should be performed in all patients at the diagnosis and during follow-up. To date, the most widely accepted test for NETs has been CgA. An increased CgA level is 'generally considered' to be sensitive, ∼60-90%, and accurate once an NET has been identified. It is however an ineffective first-line diagnostic marker. [34] Study by Zatelli et al. indicated that CgA serum levels can be helpful for the clinical management of NETs, but with low sensitivity and specifity for diagnostic purposes. On the other hand, the main utility of CgA measurement may be in patient monitoring. [35] CgA has been described to be the best marker in patients with NETs in both sporadic and MEN1-related forms, and the highest CgA values usually occur in patients with metastatic disease. [36] In this study, diagnosis of vipoma was established in accordance with clinical symptom of diarrhea (30/30, 100%), imaging studies (28/30, 93.3%), hypokalemia (25/30, 83 .3%) and VIP levels (23/30, 76.6%) in patients. Moreover, Al-Risi et al. in a retrospective study evaluated diagnostic utility and limitations of chromogranin A as a biomarker for NETs in a tertiary care hospital in Oman. Authors concluded that serum CgA is a sensitive and effective noninvasive laboratory test for the clinical detection and management of NETs. [37] 
Differential diagnosis
Causes of secretory diarrhea in adults of the developed countries include laxative abuse, carcinoid syndrome, microscopic colitis, and bile salt malabsorption due to ileal resection. Though more common in the developing countries, diarrhea due to infection from vibrio cholera, enterotoxigenic Escherichia coli may also need to be ruled out after careful assessment of the history. Secretory diarrhea may occasionally occur in association with gastrointestinal disorders like crohnˊs disease and the short bowel syndrome. In rare cases, Munchausen syndrome by proxy may also need to be ruled out. In children, rarely inherited electrolyte transport defects, like congenital chloride diarrhea and congenital sodium diarrhea, may cause secretory diarrhea. These present in early infancy. [38] Treatment Because most pNETs are indolent, a wait-and-see approach has historically predominated. The treatment strategy for pNETs has undergone a paradigm shift in the last 10-20 years. An aggressive approach has become popular in academic centers throughout the world. The aggressive approach is based on the reasonable assumptions that patients benefit from reducing the tumor burden and that interventions are increasingly safer in academic centers. Therefore, the aggressive approach advocates removing as much of primary and metastatic tumors as possible. Although no prospective randomized trials have been performed to study the efficacy and safety of the aggressive method and experience confirming it. Surgery therefore remains the only curative approach for neuroendocrine tumors whenever possible; in case of poorly differentiated tumors; surgery as well as other liver-directed therapies such as embolization are almost never applicable, and these patients are mainly managed with chemotherapy. In case of functioning well-differentiated neuroendocrine tumors, it is important to control the hormone hypersecretion, which determines symptoms, usually by the administration of SSAs. Beside surgery, a variety of therapeutic options exist for metastatic neuroendocrine disease: i.e., locoregional therapies, medical therapy including chemotherapy, biotherapy with SSAs and IFN-alpha, and more recently the molecular targeted therapies and the systemic peptide receptor radionuclide therapy. Furthermore, in highly selected patients' orthotopic liver transplantation might be considered. In this study, medical treatments include somatostatin and analogues in 18 patients (18/30, 60%), potassium supplementation in 10 patients (10/30, 33.3%), symptomatic therapy e.g., oral rehydration and intravenous fluid therapy in 7 patients (7/30, 23.3%). Surgical treatment contained caudal pancreasectomy, pylorus-preserving pancreatoduodenectomy plus resection 2 tumor and exploratory laparotomy in 2 patients (2/30, 6.6%).
Other studies in different papers
In cohort study by Gunavathy et al., they showed that patients with gasteroenteropancreatic-neuroendocrine tumors (GEP-NETs) in Malaysia commonly presented late in the disease with presence of distant metastases. Less than half had adequate hormonal and biochemical examinations performed for diagnostic as well as prognostic purposes, and only a third received systemic therapy. [39] Morover, study by Crona et al., a retrospective analysis of 972 patients with GEP-NETs treated in hospital. They concluded diversity of pNET hormone secretion either at diagnosis or during the disease course occurred in a minority of patients (9.3%). These phenomena had a major impact on patient outcome both through increased morbidity and mortality. Their results support that patients with metastatic pNETs should be monitored for clinical symptoms of secondary hormone secretion during the disease course. [40] Bloom and Polak reported 1000 adult patients with various forms of diarrhea. 39 (3.9%) patients had greatly elevated levels of VIP, and in each case, a tumor was found. In more than 50% of these patients, the tumor was successfully removed, the symptoms remitted, and the plasma levels of VIP returned to normal. Twelve patients had diarrhea secondary to thyrocalcitonin (TCT) -producing tumors of the thyroid, 13 had carcinoma of the lung, 4 had a villous adenoma of the rectum, and 24 had carcinoid tumors. All 53 of these patients had normal plasma VIP levels. Additional eleven patients had classic clinical features of the VIPoma syndrome in whom VIP levels were normal and no tumor was found. They probably were secreting an unidentified humoral substance with the biological properties of VIP.
conclusIon
The clinical symptoms that accompany VIPoma most commonly include watery diarrhea, hypokalemia and achlorhydria (or metabolic acidosis). This collection of symptoms is also known as WDHA syndrome. Timely diagnosis and appropriate treatment of vipoma prevent hazardous complications of this entity. Ongoing research is needed for more identification of disease and detection of newer tumor markers for early detection, adequate treatment and metastatic prevention.
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